SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 6, 2004
Penwest Pharmaceuticals Co.
(Exact name of registrant as specified in charter)
| | | | | |
| Washington | | 000-23467 | | 91-1513032 |
| |
| |
|
(State or other juris-
diction of incorporation | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | |
39 Old Ridgebury Road, Suite 11
Danbury, Connecticut | | 06810-5120 |
| |
|
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (877) 736-9378
(Former name or former address, if changed since last report)
TABLE OF CONTENTS
Item 5. Other Events and Required FD Disclosure
Penwest Pharmaceuticals Co. issued a press release on May 6, 2004 announcing the outcome of Endo Pharmaceuticals Inc.’s recent meeting with the FDA regarding the New Drug Application for oxymorphone ER filed by Endo. The press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
| | | |
| Exhibit No. | | Description |
| |
| 99.1 | | Press release dated May 6, 2004. |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
| 99.1 | | Press release dated May 6, 2004. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| Date: May 6, 2004 | | PENWEST PHARMACEUTICALS CO. |
| |
| | | By: /s/ Jennifer L. Good
Jennifer L. Good
Senior Vice President, Finance and
Chief Financial Officer |
